ESCMID COVID-19 Living Guidelines: drug treatment and clinical management

The draft manuscript of the „ESCMID COVID-19 Living Guidelines: drug treatment and clinical management” has now entered the Public Consultation Phase.

ESCMID members wishing to comment on the manuscript should write to guidancedocuments[at]escmid.org indicating their ESCMID membership number.

You will receive the confidential manuscript, along with the comments form for listing feedback and the together with the template to register their comments and the AGREE GLOBAL RATING SCALE form to be completed (More information about the AGREE II tool can be found here).

Please note that by accepting to participate to the Public Consultation Phase, you agree to commit to confidentiality and to respond within the deadline.

The deadline to provide feedback and comments is 7 October 2021.